- Home
- ILMN vs RPRX Comparison
ILMN vs RPRX Comparison
Compare ILMN & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILMN
- RPRX
- Stock Information
- Founded
- ILMN 1998
- RPRX 1996
- Country
- ILMN United States
- RPRX United States
- Employees
- ILMN N/A
- RPRX N/A
- Industry
- ILMN Medical Specialities
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- ILMN Health Care
- RPRX Health Care
- Exchange
- ILMN Nasdaq
- RPRX Nasdaq
- Market Cap
- ILMN 15.9B
- RPRX 14.2B
- IPO Year
- ILMN 2000
- RPRX 2020
- Fundamental
- Price
- ILMN $76.82
- RPRX $33.21
- Analyst Decision
- ILMN Buy
- RPRX Strong Buy
- Analyst Count
- ILMN 18
- RPRX 4
- Target Price
- ILMN $138.22
- RPRX $42.50
- AVG Volume (30 Days)
- ILMN 1.9M
- RPRX 3.9M
- Earning Date
- ILMN 05-08-2025
- RPRX 05-08-2025
- Dividend Yield
- ILMN 3.90%
- RPRX 2.66%
- EPS Growth
- ILMN N/A
- RPRX 37.42
- EPS
- ILMN N/A
- RPRX 2.45
- Revenue
- ILMN $4,372,000,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- ILMN N/A
- RPRX $31.30
- Revenue Next Year
- ILMN $4.51
- RPRX $5.82
- P/E Ratio
- ILMN N/A
- RPRX $13.52
- Revenue Growth
- ILMN N/A
- RPRX 1.12
- 52 Week Low
- ILMN $68.70
- RPRX $24.05
- 52 Week High
- ILMN $156.66
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- ILMN 46.43
- RPRX 60.48
- Support Level
- ILMN $73.86
- RPRX $31.97
- Resistance Level
- ILMN $80.86
- RPRX $34.11
- Average True Range (ATR)
- ILMN 2.71
- RPRX 0.70
- MACD
- ILMN 0.68
- RPRX 0.11
- Stochastic Oscillator
- ILMN 42.26
- RPRX 77.47
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.